Clinical Medicine Insights-Oncology最新文献

{"title":"Potency and Safety of <i>KRAS</i> G12C Inhibitors in Solid Tumors: A Systematic Review.","authors":"Sara El Zaitouni, Abdelilah Laraqui, Youssra Boustany, Soukaina Benmokhtar, Hicham El Annaz, Rachid Abi, Mohamed Rida Tagajdid, Safae El Kochri, El Arbi Bouaiti, Idriss Lahlou Amine, Rabii Ameziane El Hassani, Khalid Ennibi","doi":"10.1177/11795549251331759","DOIUrl":"https://doi.org/10.1177/11795549251331759","url":null,"abstract":"<p><strong>Background: </strong>The Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, specifically the cysteine residue mutation <i>KRAS</i> (G12C), has garnered significant attention as a therapeutic target for solid cancer patients with <i>KRAS</i> mutations. Despite this interest, the efficacy and safety profiles of <i>KRAS</i> G12C inhibitors remain incompletely understood. In this study, we comprehensively evaluate the effectiveness and toxicity of relevant <i>KRAS</i> G12C inhibitors (Sotorasib, Adagrasib, Garsorasib, and Divarasib) in patients with colorectal cancer (CRC), non-small-cell lung cancer (NSCLC), and pancreatic ductal adenocarcinomas (PDAC).</p><p><strong>Methods: </strong>Our systematic review is guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We review the available clinical trials data on <i>KRAS</i> G12C inhibitors in <i>KRAS</i> G12C-mutated solid tumors. We searched PubMed, EMBASE, Cochrane Library, and major international conferences for clinical trials from January 2020 until August 2023.</p><p><strong>Results: </strong>A total of 17 eligible studies were included. <i>KRAS</i> G12C inhibitions with Sotorasib (41.2%) and Adagrasib (41.2%) each of them were reported in 7 studies. Divarasib was reported in 2 studies (11.8%) and Garsorasib was reported in 1 study (6.7%). Sotorasib showed a significant clinical benefit in terms of objective response rate (ORR) (7.1%-47%), progression-free survival (PFS) (4-6.8 months), and overall survival (OS) (4-24 months); it is more efficient in NSCLC patients with an OS of 2 years, PFS of 6.3 months, and an ORR of 41%. Adagrasib also showed significant clinical activity with an ORR (19%-53%), PFS (3.3-11.1 months), and OS (10.5-23.4 months), with more effectiveness in NSCLC patients with an OS of 23.4 months, PFS of 11.1 months, and an ORR of 53.3%. Adagrasib is more efficient with an ORR of 35.1%, PFS of 7.4 months, and an OS of 14 months in patients with PDAC, than Sotorasib which showed an ORR of 21%, PFS of 4 months, and an OS of 6.9 months. However, Adagrasib and Sotorasib are moderately efficient in CRC clinical trials.</p><p><strong>Conclusion: </strong>This study confirms that patients treated with these <i>KRAS</i> G12C inhibitors, exclusively or combined with conventional therapies, achieve better treatment responses and modulate the progressions of these solid tumors.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251331759"},"PeriodicalIF":1.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of <i>GSTM1</i> and <i>GSTT1</i> Gene Deletions in Glioma Patients in Polish Population: Pilot Study.","authors":"Jovana Todosijević Jovanović, Vladimir Gašić, Ivana Grubiša, Branka Zukić, Ludmila Grzybowska-Szatkowska, Sonja Pavlović, Vladimir Jurisic","doi":"10.1177/11795549251330712","DOIUrl":"https://doi.org/10.1177/11795549251330712","url":null,"abstract":"<p><strong>Background: </strong>Detoxification enzymes of the glutathione S-transferase (GST) family are cytosolic phase II detoxification enzymes and play an important role in the normal functioning of the human antioxidant system. When the normal function of GST is disturbed or absent, there can be disturbances in cell metabolism, proliferation, and apoptosis. Deletions in the <i>GSTM1</i> and <i>GSTT1</i> genes have been observed in several different diseases as well as in the development of cancer. There is a need to analyze the relationship between glioma and <i>GSTM1</i> and <i>GSTT1</i> gene deletion to better understand the relationship between brain tumors and <i>GST</i> polymorphisms, which is crucial for adopting a multidisciplinary approach to prognosis and treatment of brain tumors.</p><p><strong>Methods: </strong>In a cross-sectional clinical-laboratory study, gene deletions were examined in 34 patients with brain tumors originating from glial cells-gliomas and 88 healthy individuals. All participants were of Polish nationality and were not related.</p><p><strong>Results: </strong>An increase in <i>GSTM1</i> and <i>GSTT1</i> gene deletions was observed in glioma patients compared with the control group. The greatest increase showing a marked rise of 10 times (11.8% vs 1.14%, <i>P</i> < .05) is in the null genotype of both genes (<i>GSTM1-/GSTT1)</i> [odds ratio [OR] = 0.86; 95% confidence interval [CI] = 0.09-0.802] but less in the genotype with deletion of 1 <i>GST</i> gene (<i>GSTM1-/GSTT1+</i> and <i>GSTM1+/GSTT1-</i>). In addition, the findings indicated a decrease in the non-deletion genotype of both genes (GSTM1+/GSTT1+) in healthy individuals. This study showed a higher frequency of <i>GST</i> gene deletion in glioma patients in the studied population.</p><p><strong>Conclusions: </strong>Based on the obtained findings, it can be said that the examination of the selected detoxification enzymes can be a useful marker in the diagnosis of glioblastoma.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251330712"},"PeriodicalIF":1.9,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Tertiary Lymphoid Structures in Stage I Nonsmall Cell Lung Cancer: Does Location Matter?","authors":"Tianhui Xue, Xiaohuan Zhang, Qianwen Ye, Panhua Li, Yi Hu","doi":"10.1177/11795549251325061","DOIUrl":"https://doi.org/10.1177/11795549251325061","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence indicates the importance of tertiary lymphoid structures (TLSs) in predicting the outcomes of nonsmall cell lung cancer (NSCLC) patients; however, their prognostic value and correlations with peripheral inflammatory prognostic indices in stage I patients have been less well studied.</p><p><strong>Methods: </strong>Stage I NSCLC patients were recruited retrospectively; the presence and location of TLSs (peritumoral [pTLSs] and intratumoral [iTLSs]) were determined via hematoxylin and eosin (H&E)-stained slides. Peripheral inflammatory indices, including the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), prognostic nutritional index (PNI), and advanced lung cancer inflammation index (ALI), were obtained and compared among these subgroups. Disease-free survival (DFS) and overall survival (OS) were tested via Kaplan-Meier analysis, and risk factors for survival were determined via a Cox proportional hazards model.</p><p><strong>Results: </strong>A total of 24.73% and 92.73% of patients were positive for pTLSs and iTLSs, respectively. The absolute number of iTLSs was significantly greater than that of pTLSs (<i>P</i> < .001). Low preoperative LMR and ALI were detected only in patients with pTLSs but not in those without. Only pTLS was found to be a risk factor for both DFS and OS, and it was independently associated with OS (HR = 3.93, 95% confidence interval [CI] = 1.16-13.37; <i>P</i> = .028). Accordingly, patients with pTLSs had relatively poor DFS (log rank = 5.46, <i>P</i> = .019) and OS (log rank = 10.48, <i>P</i> = .001) rates.</p><p><strong>Conclusions: </strong>Among the heterogeneous results concerning the prognostic value of pTLSs and iTLSs in stage I NSCLC, our results for the first time indicated that the presence of pTLSs may predict poor outcomes in these patients and no correlation of iTLSs with the outcomes was validated; however, additional studies with large sample size are needed in future.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251325061"},"PeriodicalIF":1.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Different Cervical Cytokine Expression in High-Risk Human Papillomavirus-Infected Patients With Cervical Cancer and Its Precancerous Lesions.","authors":"Shamoli Saha, Sharmin Sultana, Raad Rahmat, Tahmina Akther, Ashrafun Nessa, Munira Jahan","doi":"10.1177/11795549251316767","DOIUrl":"10.1177/11795549251316767","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is the second most common cancer in Bangladesh and is primarily caused by persistent high-risk human papillomavirus (HR-HPV) infection. Several risk factors, including immunological, genetic, environmental, and viral factors, may contribute to the development of cervical cancer. Moreover, a disruption in an otherwise delicate balance between immune response and cytokine production may lead to diseased states. Henceforth, this study aimed to determine and compare selected cytokines, including interleukin-6 (IL-6), interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interferon-gamma (INF-γ), interleukin-10 (IL-10), GM-CSF, interleukin-8 (IL-8), and MCP-1 among HR-HPV-infected patients with cervical cancer, precancer individuals, and healthy participants to test the propensity of these cytokines to serve as predictive biomarkers for the detection of cervical cancer during its early stages.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on female patients visiting two referral hospitals in Bangladesh from September to November 2022. Among them, 80 women were enrolled in the study as patients with cervical cancer and precancerous lesions along with HPV DNA-negative healthy individuals. The selected cytokines in the cervical swab were estimated by flow cytometry.</p><p><strong>Result: </strong>Cervical cancer and precancer were primarily detected in patients aged above 40 years (73.3% and 46.7% of the patients in the respective groups). Other significant risk factors, including poor educational, socioeconomic status and nutritional conditions, age of first coitus, multiparity, and tobacco and betel nut consumption, were found significant for the development of cervical cancer and precancer (<i>P</i> < .05). The levels of IL-6, IL-1β, IL-10, IL-8, and MCP-1 were substantially elevated in patients with cancer than in patients with precancer and healthy individuals (<i>P</i> < .001). Moreover, the levels of IL-6, IL-1β, IL-10, and IL-8 were also significantly increased in patients with precancer than in healthy individuals (<i>P</i> < .05).</p><p><strong>Conclusions: </strong>Thus, IL-6, IL-1β, IL-10, IL-8, and MCP-1 can be used as potential biomarkers for diagnostic and prognostic purposes in HPV-induced cervical cancer and precancer.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251316767"},"PeriodicalIF":1.9,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain Management Adequacy in Patients With Bone Metastases: A Secondary Analysis From the Palliative Radiotherapy and Inflammation Study Trial.","authors":"Savino Cilla, Romina Rossi, Costanza Maria Donati, Ragnhild Habberstad, Pal Klepstad, Monia Dall'Agata, Vanessa Valenti, Stein Kaasa, Federica Medici, Alessio Giuseppe Morganti, Marco Maltoni","doi":"10.1177/11795549241297054","DOIUrl":"10.1177/11795549241297054","url":null,"abstract":"<p><strong>Background: </strong>Bone metastases (BMs) are a common complication in patients with cancer, often leading to significant pain that adversely affects quality of life, necessitating effective pain management strategies. This study aims to evaluate the effectiveness of pain management in patients with BMs undergoing palliative radiotherapy and to identify determinants of pain management adequacy.</p><p><strong>Methods: </strong>We conducted an observational analysis of 560 patients from the Palliative Radiotherapy and Inflammation Study (PRAIS) trial across several European centers, focusing on the Pain Management Index (PMI) for assessing pain management adequacy. Key predictors examined included Karnofsky Performance Status (KPS), treatment setting, primary tumor type, and site of BMs.</p><p><strong>Results: </strong>Our findings indicate that 19.0% of patients experienced inadequate pain management (PMI < 0). Specifically, patients with KPS ⩾ 90 had a notably lower rate of adequate analgesic therapy (59.3%) compared with those with a KPS < 90 (85.0%). Among outpatients, 23.7% reported inadequate pain management, contrasted with a significantly lower inadequacy rate (3.8%) in palliative care or hospice settings. In addition, in outpatients, pain management adequacy varied with the primary tumor type, showing improved outcomes for patients with lung cancer (89.2%) versus other primary tumors (79.1%). Moreover, in non-outpatients, pain management was less effective for patients receiving radiotherapy on pelvic BMs (89.5%) compared with other sites (95.7%).</p><p><strong>Conclusion: </strong>Although overall rates of inadequate pain management were lower than seen in previous studies, significant variability exists based on patient health status, care setting, primary tumor type, and site of BMs. These results underscore the need for personalized pain management approaches and highlight specific areas for improvement in outpatient settings and among patients with generally good health but significant pain from BMs.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549241297054"},"PeriodicalIF":1.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reading Between the Lines: Complete Blood Count-Derived Parameters as Prognostic Factors in Patients With Newly Diagnosed Acute Myeloid Leukemia.","authors":"Paulina Stefaniuk, Justyna Muzyka-Kasietczuk, Dorota Koczkodaj, Marek Hus, Monika Podhorecka","doi":"10.1177/11795549251321360","DOIUrl":"10.1177/11795549251321360","url":null,"abstract":"<p><strong>Background: </strong>Research proved the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and red blood cell distribution width (RDW) in some hematological malignancies. This study aimed to analyze the role of pretreatment NLR, LMR, PLR, RDW coefficient of variation (RDW-CV), and RDW standard deviation (RDW-SD) as prognostic markers for acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>This retrospective cohort study included 204 patients newly diagnosed with AML in the Department of Hematooncology and Bone Marrow Transplantation of the Medical University of Lublin.</p><p><strong>Results: </strong>In the univariate models, higher RDW-CV and lower LMR predicted a poorer response to induction chemotherapy (odds ratio [OR] = 1.21, 95% confidence interval [CI95] = [1.09-2.36], <i>P</i> < .001; OR = 0.95, CI95 = [0.89-0.99], <i>P</i> = .045, respectively). In the multivariate model, age of diagnosis, ECOG (Performance Status Assessment by Eastern Cooperative Oncology Group) score, cytogenetic risk, NLR, and RDW-CV affected the odds of no response to chemotherapy significantly. The risk of progression was influenced by NLR and RDW-CV in the univariate analysis (hazard ratio [HR] = 1.20, CI95 = [1.09-1.33], <i>P</i> < .001; HR = 1.10, CI95 = [1.04-1.17], <i>P</i> = .002, respectively). In the multivariate settings, cytogenetic risk, leukocyte count, and RDW-CV affected progression free survival (PFS) significantly. Based on univariate models, the risk of death, when overall survival (OS) was taken into account, was influenced by NLR, LMR, and RDW-CV (HR = 1.05, CI95 = [1.00-1.09], <i>P</i> = .034; HR = 0.94, CI95 = [0.89-0.98], <i>P</i> = .010; HR = 1.06, CI95 = [1.01-1.10], <i>P</i> = .014, respectively).</p><p><strong>Conclusions: </strong>Higher NLR, higher RDW, lower LMR, and possibly lower PLR are poor prognostic factors that may help in the risk stratification of patients with AML.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251321360"},"PeriodicalIF":1.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice: \"MicroRNA-19b Downregulates NR3C1 and Enhances Oxaliplatin Chemoresistance in Colon Cancer via the PI3K/AKT/mTOR Pathway\".","authors":"","doi":"10.1177/11795549251328453","DOIUrl":"https://doi.org/10.1177/11795549251328453","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1177/11795549211012666.].</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251328453"},"PeriodicalIF":1.9,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer.","authors":"Adriana Guarino, Matteo Santoni, Martina Catalano, Giandomenico Roviello","doi":"10.1177/11795549251321147","DOIUrl":"https://doi.org/10.1177/11795549251321147","url":null,"abstract":"","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251321147"},"PeriodicalIF":1.9,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Tumor-Treating Fields and Chemoradiotherapy: Outcomes in Grade 4 Glioma Patients.","authors":"Jintan Li, Jincheng Tao, Hongyu Lu, Xiao Fan, Zhichao Wang, Yingyi Wang, Xiefeng Wang, Wei Yan, Yongping You, Yuandong Cao, Junxia Zhang","doi":"10.1177/11795549251315579","DOIUrl":"10.1177/11795549251315579","url":null,"abstract":"<p><strong>Background: </strong>Surgical intervention, complemented by radiotherapy and chemotherapy with temozolomide, constitutes the conventional treatment protocol for patients with newly diagnosed grade 4 glioma. We have conducted a research to evaluate the efficacy and safety of an integrated treatment regimen that incorporates tumor-treating fields with concurrent chemoradiotherapy.</p><p><strong>Methods: </strong>This retrospective research analyzed the clinical data of 39 adults who were newly diagnosed with World Health Organization (WHO) grade 4 gliomas at the First Affiliated Hospital of Nanjing Medical University, between February 2022 and April 2023. Each participant received a concurrent treatment regimen consisting of temozolomide (75 mg/m² daily), tumor-treating fields (200 kHz), and brain irradiation (60 Gy delivered in 30 fractions). Maintenance treatment comprised ongoing temozolomide and tumor-treating fields. Adverse events were documented in accordance with the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0) and specific grading criteria for dermatological adverse events associated with tumor-treating fields.</p><p><strong>Results: </strong>Among the 39 enrolled patients, disease progression was observed in 22 individuals (56.4%), with a median progression-free survival (PFS) of 14.2 months (95% confidence interval [CI]: 13.1-14.3 months). The median overall survival (OS) was 18.2 months (95% CI: 17.3 months to not reached). Patients diagnosed with glioblastoma had a median PFS of 13.1 months (95% CI: 12.9-14.2 months) and a median OS of 18.2 months (95% CI: 17.3 months to not reached). In contrast, patients diagnosed with astrocytoma had a median PFS of 14.3 months (95% CI: 12.8 months to not reached) and a median OS of 17.0 months (95% CI: 10.6 months to not reached). Twenty-five patients (64.1%) experienced dermatological adverse events, and 30 (77.0%) experienced mild hematological adverse reactions related to chemoradiotherapy.</p><p><strong>Conclusion: </strong>The application of tumor-treating fields concurrent with post-surgery chemoradiotherapy is both safe and effective for treating patients with newly diagnosed WHO grade 4 gliomas, exhibiting only limited toxicity.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251315579"},"PeriodicalIF":1.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Impact of Heart Failure on the Postoperative Outcomes for Lung Cancer Patients Undergoing Lobectomy and Sublobar Resection by Video-Assisted Thoracic Surgery: A Propensity Score-Matched Analysis of 2016-2020 HCUP-NIS Data.","authors":"Xiaoying He, Weibin Wu, Yan Wang, Jingyi Xiao, Juanjuan Feng, Hua Hong, Yue Chen, Rong Huang, Hongyu Guan, Hai Li","doi":"10.1177/11795549251319583","DOIUrl":"10.1177/11795549251319583","url":null,"abstract":"<p><strong>Background: </strong>The clinical impact of heart failure (HF) on postoperative outcomes following video-assisted thoracic surgery (VATS) for lung cancer resection remains controversial. This study aimed to assess patient and hospital characteristics related to the type of surgery, as well as the independent impact of HF on surgical outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective analysis using data from the National Inpatient Sample database. A total of 20 693 patients aged 18 years or older, diagnosed with lung cancer, and undergoing lobectomy or sublobar resection via VATS between 2016 and 2020 were included. Patients were stratified based on the presence of HF. The HF-present cohorts were matched to HF-absent controls using a 1:2 nearest-neighbor propensity score-matching (PSM) analysis. The matched cohorts were then compared across several endpoints, including mortality, length of stay (LOS), hospitalization costs, and postoperative complications.</p><p><strong>Results: </strong>After PSM, the study included 1781 patients who underwent lobectomy and 1157 who underwent sublobar resection, with 594 and 386 patients, respectively, having concurrent HF. In both the lobectomy and sublobar resection groups, patients with HF demonstrated significantly higher in-hospital mortality rates (<i>P</i> < .001), longer LOS (<i>P</i> < .001), increased total hospital charges (<i>P</i> < .001), and a greater risk for overall postoperative complications (<i>P</i> < .001).</p><p><strong>Conclusions: </strong>Among patients with lung cancer undergoing VATS, the presence of HF is associated with an increased risk of postoperative complications. This finding underscores the necessity for enhanced monitoring and care for patients with HF should be treated during the postoperative recovery phase.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251319583"},"PeriodicalIF":1.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}